- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Aberrations of the eye.
Displaying page 1 of 1.
EudraCT Number: 2016-001091-30 | Sponsor Protocol Number: FG-PRE-101 | Start Date*: 2016-10-17 |
Sponsor Name:ORASIS Pharmaceuticals Ltd | ||
Full Title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Repeated Administration, Crossover Study to Establish Safety, Tolerability, and Efficacy of PresbiDrops in Presbyopic Subjects | ||
Medical condition: Presbyopia is part of the natural ageing process of the eye. It is usually noticed at around the age of 40 years. The main symptom of this condition is a progressive blurring of vision when perform... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001286-16 | Sponsor Protocol Number: APP-study | Start Date*: 2018-11-05 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Low-dose Atropine for the Prevention of Childhood Myopia Progression in Danish Children (APP-study) | |||||||||||||
Medical condition: Childhood myopia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004505-27 | Sponsor Protocol Number: DZB-CS-202 | Start Date*: 2020-07-09 |
Sponsor Name:Basilea Pharmaceutica International Ltd. | ||
Full Title: A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic a... | ||
Medical condition: HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) FR (Ongoing) BE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000359-15 | Sponsor Protocol Number: DZB-CS-201 | Start Date*: 2020-02-11 | |||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd. | |||||||||||||
Full Title: An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02) | |||||||||||||
Medical condition: urothelial cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
